Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Fulgent Genetics, Inc.

Fulgent Genetics is a technology company that provides genetic testing and diagnostic services. The company offers a range of genetic tests including oncology, hereditary cancer, known mutation, newborn genetics, and pharmacogenetics.

Fulgent Genetics

Picture Genetics

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us.

Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health.

We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.

- Our Products & Services -

Fulgent Genetics
https://www.fulgentgenetics.com/

Fulgent Oncology
https://fulgentoncology.com/

Fulgent BioPharma
https://biopharma.fulgent.com/

Picture Genetics
https://picturegenetics.com/

HelioLiver
https://www.helioliver.com/

Fulgent is a CLIA-certified and CAP-accredited laboratory.

_____________
NASDAQ: FLGT

We’ll be in #NewOrleans next month for the #NSGC24 Annual Conference, where we’re excited to highlight our new #KNOVA Prenatal Cell-Free DNA Screening (NIPT/NIPS) test and our new RNA-Integrated Sequence Evaluation (RISE) service option. 

To chat with us about these or anything else, email info@FulgentGenetics.com and we’ll set up a time to meet in New Orleans! We hope to see you there. 

#PrenatalScreening #NIPT #RISE

#AstraZeneca and #Daiichi Sankyo have made history with the approval of Enhertu in the US! This groundbreaking achievement marks a significant milestone in oncology as Enhertu becomes the first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors. 

At Fulgent, we’re eager to support HER2 testing using our state-of-the-art pathology facilities. Reach out to bd@fulgentgenetics.com to learn more.   

Here's to the positive impact Enhertu will have on patients and families worldwide! #Enhertu #Oncology #IHC #HER2 #pathology

We’ll be in Washington D.C. from November 1-5 next week for #ASHG23. Our team will be at booth 510 to talk about the latest in Fulgent BioPharma, Fulgent Oncology, Beacon carrier screening, and more. We’ll also have a presentation about the role of CNV’s in the etiology for chronic kidney disease.

Join us in San Diego from November 1-5 for #SITC at booth 333. We’ll share the latest developments from Fulgent BioPharma and Fulgent Oncology. Be sure to check out our presentations on Nov 4.

Fulgent BioPharma is here at #ASCO24! Let us know if you would like to meet to discuss our oncology biomarker services, including liquid biopsy molecular profiling, solid tumor profiling and more. Contact us for a meeting: http://tiny.cc/Fulgent 

#ASCO #Clinicaltrials #BioPharma #Oncology

Meet up with the Fulgent BioPharma team in Berlin this weekend for #ESHGS2024 #hybridconference. You can find us at stand #386. Talk to our team to learn more about our wide array of NGS tests and lab services, including prenatal testing, hereditary cancer, and more.

COM:FULGENTGENETICS

Fulgent Genetics

Last Close

16.95

22/11 21:00

Market Cap

586.52M

Beta: -

Volume Today

422.85K

Avg: -